To further highlight the utility of our resource, we validate the selective localization of the immune checkpoint protein CD276 (B7-H3) to tumor vasculature (MVP), information that may help explain and overcome challenges with immunotherapies focusing only on canonical proteins such as PD-1 and CTLA446. This evidence concerns the gene CD276 and neoplasm.